Business Wire

AL-ADTRAN

Share
Adtran launches new FSP 3000 OLS to unlock the coherent optical edge

Adtran today launched its FSP 3000 Edge OLS, an open line system designed for the new generation of coherent edge access, aggregation and metro networks. It enables operators to efficiently address soaring bandwidth demand from mobile, broadband and enterprise applications by leveraging the latest coherent pluggable technology in this cost-sensitive part of the network. The FSP 3000 Edge OLS has been specifically engineered for the use of coherent transmission at the optical edge, including the recently introduced Coherent 100ZR, as well as 400ZR optics. By utilizing power-optimized wavelength broadcasting technology and a gridless architecture, the solution enables a simple and affordable optical layer with compact and flexible nodes that can transport any coherent signal and baud rate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005466/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s FSP 3000 Edge OLS will help operators deploy coherent optical edge networks in the most effective way possible. (Graphic: Business Wire)

“At OFC, we showcased our world-first QSFP28 Coherent 100ZR, bringing robust, efficient and simple coherent technology to the edge of the network. Now we’re complementing this innovative transceiver with an OLS optimized for the cost-efficient transport of coherent technology at the optical edge. Providing maximum performance, it meets all critical demands of edge aggregation networks, including scalability, compact design, low power consumption, operational simplicity and extended temperature operation for outdoor deployment,” said Christoph Glingener, CTO at Adtran. “Our pioneering work at the network edge is creating whole new opportunities for service providers.”

The Adtran FSP 3000 Edge OLS is an open line system engineered to help operators roll out coherent optical edge networks in the most cost-effective and flexible way possible. With ZR-optimized technology for minimal insertion loss, the new OLS enables the use of ZR coherent optics at the optical edge in multiple use cases, including linear, hub-and-spoke or tree topologies. With its modular design, it empowers users to mix and match elements to create a solution that meets their exact needs. What’s more, the Adtran FSP 3000 Edge OLS facilitates the development of a compact and efficient optical layer with low-power nodes that require minimal space and can function in an extended temperature range. This enables deployment in outdoor environments, such as street cabinets.

“Our FSP 3000 Edge OLS offers a major boost to operators looking for an affordable way to tackle relentless growth in data traffic. Low-cost yet highly flexible, it can scale to transparently accommodate any line speed or baud rate. Now there’s a clear route to deploying an optical layer that leverages coherent transport technology, including 100ZR and 400ZR optics, and meets the stringent requirements of the new optical edge,” commented Henning Hinderthür, VP of product line management, Optical Networks at Adtran. “Our FSP 3000 Edge OLS harnesses advanced wavelength broadcast technology for new levels of power and cost efficiency. It’s also ready to be deployed anywhere from central offices to street furniture.”

Further details on Adtran’s FSP 3000 Edge OLS are available in these slides.

A supporting product video is available to watch.

A solution brief can also be downloaded.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005466/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye